AGP Picks
View all

MIMOSA Diagnostics wins OCI’s 2026 Mind2Market Award

Oct. 22, 2026
MIMOSA Diagnostics wins OCI’s 2026 Mind2Market Award
By AI, Created 13:10 UTC, Oct 22, 2026, AGP -

MIMOSA Diagnostics has received the Ontario Centre of Innovation’s 2026 Mind2Market Award for MIMOSA Pro, recognizing the research-to-commercialization path behind its tissue-health imaging device. The Toronto company says the pocket-sized tool helps clinicians spot pressure injuries and deep tissue injuries earlier and manage chronic wounds across care settings.

Why it matters: - The award spotlights a Canadian medtech product that moved from research to clinical use with OCI-backed support. - MIMOSA Pro is designed to help clinicians detect tissue damage earlier, including when skin still looks intact or signs are harder to see on darker skin tones. - The device is used in hospital, mobile wound care and post-acute care settings in the United States and Canada.

What happened: - MIMOSA Diagnostics Inc. won the Ontario Centre of Innovation’s 2026 Mind2Market Award, sponsored by GeoMate. - OCI presented the award at its Annual General Meeting in Toronto on October 20, 2026. - Co-founder Dr. General Leung accepted the award on MIMOSA’s behalf. - The award recognizes the strongest OCI-supported partnership between industry and the research community that led to commercialization.

The details: - MIMOSA Pro is a pocket-sized device that combines near-infrared spectroscopy, long-wave infrared thermography, wound measurement and a digital image in a single capture. - The device is FDA Class II/510(k) and Health Canada approved. - MIMOSA Pro captures tissue oxygenation, skin surface temperature, wound size and a standardized digital photo in one second. - Results are sent to a secure, HIPAA-compliant web portal for longitudinal tracking. - MIMOSA is developing algorithms that account for skin melanin content to support consistent assessments across skin tones. - The device supports early identification of pressure injuries and deep tissue injuries, chronic wound management, and continuity from admission to discharge. - The same record can be used across hospital inpatient, hospital outpatient and skilled nursing settings. - The underlying research was developed at the Keenan Research Centre for Biomedical Science at St. Michael’s Hospital in Toronto. - OCI’s Collaborate 2 Commercialize program supported MIMOSA’s machine-learning work on wound image extraction. - OCI’s Life Sciences Innovation Fund supported commercialization of MIMOSA Pro, including entry into the United States. - Research partners on the collaboration included the University of Toronto and York University. - Past Mind2Market recipients include Gotcare, Pulsenics, TROES, Flosonics Medical and InteraXon.

Between the lines: - The award signals that OCI sees MIMOSA’s path from lab research to market as a model for commercialization. - The company is positioning MIMOSA Pro around objective measurement, not visual inspection alone, which matters when wounds begin beneath the skin. - The focus on melanin-aware algorithms points to a broader push for more consistent assessment across diverse patient populations.

What’s next: - MIMOSA Diagnostics will likely continue expanding clinical use of MIMOSA Pro in North America. - The company is also advancing software that can better account for differences in skin tone. - OCI’s recognition may help strengthen visibility for future research-commercialization partnerships.

The bottom line: - MIMOSA Diagnostics turned an OCI-supported research collaboration into a commercially available wound-imaging device, and OCI is now holding it up as a commercialization success story.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Science Times Observer

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Science Times Observer

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.